GSK and Sanofi make global Covid vaccine supply deal

GSK and Sanofi make global Covid vaccine supply deal

Publishedduration27 minutes ago

Drug companies GSK and Sanofi will supply 200 million doses of their coronavirus vaccine candidate to a global inoculation scheme.

The two companies' vaccine is going through the first stages of testing.

There is no internationally-approved treatment for Covid-19, which has killed more than 1.16 million people.

Meanwhile, GSK said it expects 2020 earnings to be at the lower end of a forecast due to Covid disruption to vaccinations for other diseases.

180 nations

GSK and Sanofi will supply their vaccine candidate to the Covax scheme, which is backed by the World Health Organization (WHO).

Covax, which aims to deliver 2 billion vaccine doses around the world by the end of 2021, has already signed agreements this year with AstraZeneca and Novavax.

It aims to discourage national governments from hoarding Covid-19 vaccines and to